<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T04:28:51Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/10183" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/10183</identifier><datestamp>2025-10-24T08:57:06Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>com_2072_378071</setSpec><setSpec>col_2072_378092</setSpec><setSpec>col_2072_378097</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2025-10-24T08:57:06Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_11351_10183">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:11351/10183</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin</dc:title>
               <dc:creator>Torres-Duran, María</dc:creator>
               <dc:creator>Montero Martínez, Carmen</dc:creator>
               <dc:creator>Priegue Carrera, Ana</dc:creator>
               <dc:creator>Amaro, Rosanel</dc:creator>
               <dc:creator>Barrecheguren, Miriam</dc:creator>
               <dc:creator>Barrio Guirado, MªAngeles</dc:creator>
               <dc:creator>García-Meseguer, Pilar</dc:creator>
               <dc:creator>López-Campos Bodineau, José Luis</dc:creator>
               <dc:creator>Calle Rubio, Myriam</dc:creator>
               <dc:creator>Montoro-Ronsano, J. Bruno</dc:creator>
               <dc:creator>Miravitlles, Marc</dc:creator>
               <dc:subject>Pulmons - Malalties - Tractament</dc:subject>
               <dc:subject>Alfa 1-antitripsina - Ús terapèutic</dc:subject>
               <dc:subject>Teràpia intravenosa</dc:subject>
               <dc:subject>CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Serpins::alpha 1-Antitrypsin</dc:subject>
               <dc:subject>Other subheadings::Other subheadings::/therapeutic use</dc:subject>
               <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Administration Routes::Administration, Intravenous::Infusions, Intravenous</dc:subject>
               <dc:subject>DISEASES::Respiratory Tract Diseases::Lung Diseases</dc:subject>
               <dc:subject>COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::serpinas::alfa 1-antitripsina</dc:subject>
               <dc:subject>Otros calificadores::Otros calificadores::/uso terapéutico</dc:subject>
               <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::vías de administración de medicamentos::administración intravenosa::infusiones intravenosas</dc:subject>
               <dc:subject>ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares</dc:subject>
               <dc:description>Alpha-1 antitrypsin deficiency; Sugmentation therapy; Self-administration</dc:description>
               <dc:description>Deficiència d'alfa-1 antitripsina; Teràpia d'augment; Autoadministració</dc:description>
               <dc:description>Deficiencia de alfa-1 antitripsina; Terapia de aumento; Autoadministración</dc:description>
               <dc:description>Purpose: Administration of exogenous alpha-1 antitrypsin (AAT) is the only specific therapy for the management of pulmonary morbidity in patients with AAT deficiency. It requires weekly or biweekly intravenous infusions, which may impact patient independence and quality of life. Self-administration of AAT therapy is an alternative to reduce the burden for patients who require AAT therapy. We presented herein experts’ recommendations for the implementation of a program for the self-administration of AAT.&#xd;
Methods: This project was conducted using a modified nominal group technique and was undertaken in two online meetings involving the participation of 25 experts: specialists in pulmonology (n=17), nurses (n=5) and hospital pharmacists (n=3).&#xd;
Results: The following issues were discussed, and several recommendations were agreed upon on the following topics: a) patient profile and clinical evaluation, establishing selection criteria that should include clinical as well as social criteria; b) role of health care professionals, suggested roles for specialists in pulmonology, nurses, and hospital pharmacists; c) training by the nurse, including recommendations before initiating the training and the content of the training sessions; and d) logistic issues and follow-up, adherence, and patient support.&#xd;
Conclusion: We expect this proposal to increase awareness of this therapeutic alternative and facilitate the implementation of self-administration programs, thus contributing to optimizing the patient experience with AAT therapy. Further research on the outcomes of these programs, especially from the patient perspective, will also help to improve their design and implementation.</dc:description>
               <dc:description>This project was funded by CSL Behring España.</dc:description>
               <dc:date>2025-10-24T08:57:06Z</dc:date>
               <dc:date>2025-10-24T08:57:06Z</dc:date>
               <dc:date>2023-08-30T11:04:27Z</dc:date>
               <dc:date>2023-08-30T11:04:27Z</dc:date>
               <dc:date>2023-08-04</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/11351/10183</dc:identifier>
               <dc:relation>International Journal of Chronic Obstructive Pulmonary Disease;18</dc:relation>
               <dc:relation>http://dx.doi.org/10.2147/COPD.S410611</dc:relation>
               <dc:rights>Attribution-NonCommercial 4.0 International</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by-nc/4.0/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>Dove Medical Press</dc:publisher>
               <dc:source>Scientia</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>